0001415889-23-007691.txt : 20230509
0001415889-23-007691.hdr.sgml : 20230509
20230509181902
ACCESSION NUMBER: 0001415889-23-007691
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230505
FILED AS OF DATE: 20230509
DATE AS OF CHANGE: 20230509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Henderson Jeffrey William
CENTRAL INDEX KEY: 0001324015
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32335
FILM NUMBER: 23903707
MAIL ADDRESS:
STREET 1: 7000 CARDINAL PLACE
CITY: DUBLIN
STATE: OH
ZIP: 43017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001159036
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 880488686
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 794-8889
MAIL ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC
DATE OF NAME CHANGE: 20040312
FORMER COMPANY:
FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC
DATE OF NAME CHANGE: 20010912
4
1
form4-05092023_100551.xml
X0407
4
2023-05-05
0001159036
HALOZYME THERAPEUTICS, INC.
HALO
0001324015
Henderson Jeffrey William
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
SAN DIEGO
CA
92130
true
false
false
false
0
Common Stock
2023-05-05
4
A
0
8065
0
A
47110
D
Option to Purchase Common Stock
31
2023-05-05
4
A
0
11371
0
A
2024-05-05
2033-05-05
Common Stock
11371
11371
D
Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.
Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.
/s/ James Oehler, Attorney-in-Fact
2023-05-09